Abstracts tagged "giant cell arteritis"

Abstract Number: 2754 • 2018 ACR/ARHP Annual Meeting
Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients
Monica Calderón Goercke¹, Diana Prieto Peña¹, Javier Loricera², Vicente Aldasoro³, Santos Castañeda⁴, Ignacio Villa-Blanco⁵, Alicia Humbría⁴, Clara Moriano Morales⁶, Susana Romero-Yuste⁷, Francisco Javier Narváez⁸, Catalina Gómez-Arango⁹, Eva Perez Pampín¹⁰, Rafael Melero¹¹, Elena Becerra-Fernández¹², Marcelino Revenga Martínez¹³, Noelia Álvarez-Rivas¹⁴, Carlos Galisteo¹⁵, Francisca Sivera¹⁶, Alejandro Olivé-Marqués¹⁷, Maria Concepcion Alvarez de Buergo¹⁸, Luisa Marena Rojas Vargas¹⁹, Carlos Fernandez-Lopez²⁰, Francisco Navarro²¹, Enrique Raya Álvarez²², Eva Galindez-Agirregoikoa²³, Beatriz Arca²⁴, Roser Solans²⁵, Arantxa Conesa²⁶, Cristina Hidalgo-Calleja²⁷, Carlos Vázquez²⁸, Pau Lluch²⁹, Jose Andrés Román Ivorra³⁰, Sara Manrique-Arija³¹, Paloma Vela³², Eugenio De Miguel³³, Carmen Torres-Martín³⁴, Juan Carlos Nieto³⁵, Carmen Ordas-Calvo³⁶, Eva Salgado-Pérez³⁷, Cristina Luna Gómez³⁸, Francisco J. Toyos Sáenz de Miera³⁹, Nagore Fernandez-Llanio Cornella⁴⁰, Antonio García⁴¹, Carmen Larena⁴², Belén Atienza-Mateo⁴³, José Luis Martín-Varillas⁴³, Natalia Palmou-Fontana⁴³, Vanesa Calvo-Río⁴³, Carmen González-Vela⁴⁴, Alfonso Corrales⁴³, María Varela-García⁴⁵, Elena Aurrecoechea⁴⁶, Raquel Dos Santos⁴⁷, Angel García-Manzanares¹², Norberto Ortego Centeno⁴⁸, Sabela Fernández⁴⁹, Francisco Ortiz-Sanjuán⁵⁰, Montserrat Corteguera³⁴, Miguel Angel González-Gay⁴³, José Luis Hernández² and Ricardo Blanco⁴³, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁴Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁷Hospital de Pontevedra. Spain, Pontevedra, Spain, ⁸Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ⁹Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ¹⁰Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹¹Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹²Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, ¹³Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ¹⁴Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁵Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, ¹⁶Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁷Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁸Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ¹⁹Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ²⁰Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, ²¹Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ²²Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²³Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²⁴Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ²⁵Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁶Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ²⁷Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, ²⁸Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, ²⁹Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ³⁰Hospital La Fe. Valencia. Spain, Valencia, Spain, ³¹Medicine, University of Málaga, MÁLAGA, Spain, ³²Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ³³Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ³⁴Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, ³⁵Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁶Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ³⁷Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, ³⁸Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ³⁹Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ⁴⁰Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ⁴¹Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, ⁴²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁴Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁵Complejo Hospitalario de Navarra, Navarra, Spain, ⁴⁶Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴⁷Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, ⁴⁸Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁴⁹Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ⁵⁰Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain
Background/Purpose: Giant cell arteritis (GCA) can be refractory to corticosteroid therapy (1-3). Tocilizumab (TCZ) has been approved in the treatment of GCA. There are no…
Abstract Number: 2755 • 2018 ACR/ARHP Annual Meeting
Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis
Monica Calderón Goercke¹, Javier Loricera², Diana Prieto Peña¹, Clara Moriano Morales³, Elvira Diez Alvarez⁴, Francisco Javier Narváez⁵, Antonio Mera⁶, Eva Perez Pampín⁶, Vicente Aldasoro⁷, María Varela-García⁸, Noelia Álvarez-Rivas⁹, Ceferino Barbazan¹⁰, Carmen Ordas-Calvo¹¹, Francisca Sivera¹², Cristina Luna Gómez¹³, Francisco J. Toyos Sáenz de Miera¹⁴, Arantxa Conesa¹⁵, Francisco Navarro¹⁶, Belén Atienza-Mateo¹⁷, José Luis Martín-Varillas¹⁷, Eva Galindez-Agirregoikoa¹⁸, Vanesa Calvo-Río¹⁷, Carmen González-Vela¹⁹, Natalia Palmou-Fontana², José Luis Hernández², Miguel Angel González-Gay² and Ricardo Blanco¹⁷, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ⁶Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ⁷Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁸Complejo Hospitalario de Navarra, Navarra, Spain, ⁹Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹¹Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ¹²Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹³Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ¹⁴Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ¹⁵Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ¹⁶Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ¹⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁸Rheumatology, University Hospital of Basurto, Bilbao, Spain, ¹⁹Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a special predilection for extracranial branches of the external carotid artery. Among its most…
Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Sebastian H. Unizony¹, Jinglan Pei², Páris N. Sidiropoulos², Jennie H. Best², Christine Birchwood² and John H. Stone³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, CA, ³Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…
Abstract Number: 2761 • 2018 ACR/ARHP Annual Meeting
High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort
Sarah H. Chung¹, Meredith B. Morcos¹ and Bernard Ng^1,2, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: Temporal artery biopsy (TAB) currently remains the gold-standard confirmatory test for the diagnosis of giant cell arteritis (GCA); positive TAB justifies long-term steroid use…
Abstract Number: 2763 • 2018 ACR/ARHP Annual Meeting
Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
Matthew J. Koster¹, Melissa Snyder², Michel Villatoro-Villar¹, Cynthia S. Crowson³, Tanaz A. Kermani⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: To investigate the utility of serum free light chains (FLC), antiphospholipid antibodies (APL), and cytokines in the evaluation of patients with biopsy-proven giant cell…
Abstract Number: 823 • 2018 ACR/ARHP Annual Meeting
Survival of Biopsy Proven Giant Cell Arteritis in Northern Italy: Correlation with Clinical, Laboratory and Histopathological Findings
Luigi Boiardi¹, Pierluigi Macchioni², Francesco Muratore³, Mariagrazia Catanoso², Alberto Cavazza⁴, Pamela Mancuso⁵, Luca Cimino⁶, Giovanna Restuccia⁷ and Carlo Salvarani⁸, ¹Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ³Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁴Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁵Interinstitutional Epidemiology Unit, Azienda USL di Reggio Emilia (Local Health Authority) and Azienda Ospedaliera IRCCS di Reggio Emilia,, Reggio Emilia, Italy, ⁶Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁷Rheumatology Unitn, Arcispedale S Maria Nuova, IRCCS, 42100, Italy, ⁸Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy
Background/Purpose: To correlate survival with clinical, laboratory and histopathological findings in a population based cohort of patients with biopsy-proven giant cell arteritis (GCA) living in…
Abstract Number: 2764 • 2018 ACR/ARHP Annual Meeting
Incidence, Characteristics and Management of Giant Cell Arteritis in France: A Study Based on National Health Insurance Claims Data
Valérie Devauchelle-Pensec¹, Eric Hachulla², Marc Paccalin³, Sophie Gandon⁴, Isabelle Idier⁵, Maeva Nolin⁶, Manon Belhassen⁶ and Alfred Mahr⁷, ¹Department of Rheumatology and Unit of Immunology, University Medical School, Brest, France, ²Department of Internal Medicine, University Lille Nord-de-France, Lille, France, ³Department of Geriatric Medicine, University Hospital, Poitiers, France, ⁴Clinical Operation, Roche SAS, Boulogne-Billancourt, France, ⁵Medical department, Chugai Pharma France, Paris La Defense, France, ⁶PELyon, Pharmacoepidemiologie, Lyon, France, ⁷Hospital Saint-Louis, University Paris Diderot, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is an immune-mediated, primary systemic vasculitis that affects large and medium-sized arteries. GCA may cause vision loss in up to…
Abstract Number: 1883 • 2018 ACR/ARHP Annual Meeting
Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden
Pavlos Stamatis¹, Aleksandra Turkiewicz², Martin Englund², Goran Jönsson³, Jan-Åke Nilsson⁴, Carl Turesson⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Previous studies have implicated infections as a risk factor for giant cell arteritis (GCA). The purpose of this study was to investigate the association…
Abstract Number: 2768 • 2018 ACR/ARHP Annual Meeting
Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study
Elisheva Pokroy-Shapira¹, Ariela Dortort-Lazar^2,3 and Yair Molad^4,5, ¹Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Beilinson hospital Rabin Medical Center, Petah Tikva, Israel, ³Sackler Faculty of Medicine Tel Aviv university, Tel Aviv, Israel, ⁴Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Background/Purpose: Patients with giant-cell arteritis (GCA) and polymyalgia rheumatica (PMR) are treated with high cumulative glucocorticoid (GC) dose during their disease course. We sought to…
Abstract Number: 2176 • 2018 ACR/ARHP Annual Meeting
The Association of Gout with Incident Giant Cell Arteritis in Older Adults
Jasvinder A. Singh and John Cleveland, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that affects large and medium sized arteries in people 50 years or older. Gout, the most common…
Abstract Number: 2773 • 2018 ACR/ARHP Annual Meeting
Diagnostic and Therapeutic Management of a Suspected Case of GCA: An Opinion Survey
Henri Guillet¹, Raphaël Porcher², Alain Saraux³, Loïc Guillevin⁴, Luc Mouthon⁴ and Alexis Régent⁴, ¹Département d'aval des urgences, CHU Henri Mondor, Créteil, France, ²Université Paris Descartes Sorbonne Paris, Paris, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Institut Cochin, INSERM U1016, CNRS UMR 8104, PARIS, France
Background/Purpose: Giant-cell arteritis (GCA) is the most common vasculitis. Specialists have formulated recommendations on how to manage a patient with a possible diagnosis of GCA.…
Abstract Number: 2196 • 2018 ACR/ARHP Annual Meeting
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Joel S. Rosenblum¹, Kaitlin Quinn², Mark A. Ahlman³ and Peter C. Grayson⁴, ¹NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: 18F-fluorodeoxyglucose (FDG) PET may be used to quantify vascular inflammation in large-vessel vasculitis (LVV). Quantitative analysis of arterial FDG uptake has not been standardized. Delayed…
Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Judit Font Urgelles¹, Luis Rodriguez-Rodriguez², Zulema Rosales Rosado^1,2, Dalifer Freites Núñez², Leticia Leon², Inmaculada Morado¹, Esperanza Pato Cour¹, Juan A Jover Jover¹, Benjamín Fernández-Gutiérrez¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…
Abstract Number: 2197 • 2018 ACR/ARHP Annual Meeting
Steroid Bolus Leads to a Negative 18f-FDG PET/CT Scan in Large Vessel Vasculitis. Data from a Multicenter Giant Cell Arteritis Cohort Database
Paula Estrada¹, Patricia Moya², Hector Corominas³, Delia Reina⁴, Dacia Cerdà⁴, Daniel Roig Vilaseca⁴, Vanessa Navarro⁴, Sergi Heredia⁴ and Francisco Javier Narváez⁵, ¹Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, Barcelona, Spain, ²Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral,, barcelona, Spain, ⁵Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain
Background/Purpose: Giant cell arteritis (GCA) and polymialgia rheumatica (PMR) are overlapping inflammatory diseases. Large Vessel Vasculitis (LVV) is frequently present in any of the two…
Abstract Number: 2777 • 2018 ACR/ARHP Annual Meeting
Dynamics in Peripheral Blood Cell Counts in Giant Cell Arteritis before Treatment, during Treatment and in Treatment-Free Remission
Jacoba C. Graver¹, Yannick van Sleen², Wayel H. Abdulahad², Annemieke M.H. Boots², Maria Sandovici² and Elisabeth Brouwer³, ¹Rheumatoloy and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen University Medical Center, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory disease of large vessels requiring long-term treatment with glucocorticoids. The immunopathology is characterized by vessel infiltrating innate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].